Chemometec pursues cell therapy companies with tailored instrument
Chemometec's newest cell analysis instrument, which was launched in January, spearheads the company's all-important strategy to deliver instruments to biotech companies involved in cell therapy. Analyst points out the company as a potential acquisition target.
Michael Eising, CEO of Cemometec, has asked the company's sales people to aim all efforts towards one goal: the Danish company must be the leading supplier of instruments for counting and analyzing cells at those biotech companies that are currently struggling to develop cell therapies.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Chemometec launches “game changing” device
For abonnenter
Chemometec’s new growth engine could attract buyers
For abonnenter
